Comparison of the Incidence of Major Bleeding with Rivaroxaban Use among Nonvalvular Atrial Fibrillation Patients With versus Without Diabetes Mellitus

Diabetes mellitus (DM) is a common comorbidity in those with nonvalvular atrial fibrillation (NVAF). Most patients with DM and NVAF have a CHA2DS2-VASc score of ≥1 and should be considered for oral anticoagulation therapy for stroke prevention per treatment guidelines. The most important risk associated with anticoagulation is bleeding, which may be higher in those with NVAF plus DM. Our objective was to evaluate the incidence and characteristics of major bleeding (MB) in rivaroxaban users diagnosed with NVAF, further comparing those with DM versus those without DM, in a real-world clinical setting.

Source: The American Journal of Cardiology - December 7, 2016 Category: Cardiology Authors: W. Frank Peacock, Sally Tamayo, Nicholas Sicignano, Kathleen P. Hopf, Zhong Yuan, Manesh Patel Source Type: research